This is interesting but years? away.
GDNF Trial Results Published | The Cure Parkinson's Trust
Key Findings
- This was the first randomised clinical trial in Parkinson’s using an innovative delivery mechanism to administer a neurotrophic factor to a region deep inside the brain called the putamen. The device is now being used in two new trials
- The drug was safe with 99% compliance for infusions paving way for further research.
- PET scans showed the method of administration affords spatial delivery of GDNF sufficient to achieve biological effect across the entire putamen.
- By trial end, most participants saw meaningful clinical improvement although the evidence was deemed inconclusive as the trial in its final stages was not double blind without comparison group.
- A number of participants felt that the therapy had beneficial effects. The study team believe further investigation of GDNF is required - exploring increased dose and delivered over a longer period of time.
- Further testing of GDNF in a larger-scale study and including the use of higher doses is required to definitively determine whether GDNF has a future role as a neurorestorative treatment for Parkinson’s